Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...
Montreal Gazette4d
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasitamab) by its Mexican affiliate, Grupo ...